Xencor announced the selection of a Phase 3 dose for its drug XmAb819 in advanced clear cell renal cell carcinoma (ccRCC) and outlined plans for a global randomized trial. This development signals significant progress in the drug's clinical development and could lead to full or accelerated approval, potentially impacting Xencor's future revenue streams.
Xencor presented updated Phase 1 data for XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, at the 2026 ESMO Congress. The key disclosure is the selection of 400 mcg/kg as the proposed recommended Phase 3 dose for patients with advanced clear cell renal cell carcinoma (ccRCC). This is a significant step as it de-risks the next stage of clinical development and sets the stage for a global randomized trial comparing XmAb819 with tivozanib. For traders, this indicates a clear path forward for XmAb819, with potential for full approval as a monotherapy and discussions for accelerated approval in specific subsets. This news is a positive catalyst for Xencor, as successful progression through Phase 3 and subsequent approval would significantly enhance the company's valuation and market position in the oncology space. The long-term implication is a potential new revenue stream, while the short-term impact could be increased investor confidence.